Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733539 | 0.90 | HSP90AA1 (0.70) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL19004036 | 0.90 | HSP90AA1 (0.70) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL22379851 | 0.88 | HSP90AA1 (0.51) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL419313 | 0.86 | HSP90AA1 (0.71) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29425944 | 0.86 | HSP90AA1 (0.70) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29426068 | 0.83 | HSP90AA1 (0.70) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL23685612 | 0.83 | HSP90AA1 (0.65) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29426089 | 0.81 | HSP90AA1 (0.73) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29425878 | 0.80 | HSP90AA1 (0.80) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL422039 | 0.79 | HSP90AA1 (0.71) | HSP90AA1XDHKDM4EGLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646465-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | HSP90AA1 856/4885XDH 1678/4885KDM4E 2214/4885 |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | HSP90AA1 856/4885XDH 1678/4885KDM4E 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.